Construction of Enzyme Nanoreactors to Enable Tumor Microenvironment Modulation and Enhanced Cancer Treatment. Issue 5 (28th September 2020)

• Record Type: Journal Article
• Authors: Liu, Xiaowen; Hao, Yu; Popovtzer, Rachela; Feng, Liangzhu; Liu, Zhuang
• Other Names: Hou Yanglong guestEditor.; Bu Wenbo guestEditor.; Ai Hua guestEditor.; Lu Zheng‐Rong guestEditor.; Lammers Twan guestEditor.
• Is Part Of: Advanced healthcare materials. Volume 10:Issue 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-28
• Subjects: cancer treatment -- enzyme nanoreactors -- TME modulation; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.202001167
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: Enzymes play pivotal roles in regulating and maintaining the normal functions of all living systems, and some of them are extensively employed for diagnosis and treatment of diverse diseases. More recently, several kinds of enzymes with unique catalytic activities have been found to be promising options to directly suppress tumor growth and/or augment the therapeutic efficacy of other treatments by modulating the hostile tumor microenvironment (TME), which is reported to negatively impair the therapeutic efficacy of different cancer treatments. In this review, first a summary is presented on the chemical approaches utilized for the construction of distinct enzyme nanoreactors with well‐retained catalytic performance and reduced immunogenicity. Then, the utilization of such enzyme nanoreactors in attenuating tumor hypoxia, modulating extracellular matrix, and amplifying tumor oxidative stress is discussed in depth. Afterward, some perspectives are presented on the future development of such enzyme nanoreactors in TME modulation and enhanced cancer treatment. Abstract : Rational construction of enzyme nanoreactors via different delicate approaches has recently shown to be a promising option for effective cancer treatment by directly suppressing tumor growth and/or augment the therapeutic efficacy of other treatments by modulating the hostile tumor microenvironment, which is reported to negatively impair the therapeutic efficacy of diverse cancer treatments.